• http://www.revobiologics.com/sites/default/files/_rotation-images/slide-3-new.jpg

    Making a Real Difference

    With an unwavering commitment to patients with rare diseases, rEVO Biologics is moving healthcare forward.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/rotation_3.jpg

    Solutions for Rare Diseases

    rEVO Biologics is a rare disease company delivering on the promise of innovative therapies.

  • http://www.revobiologics.com/sites/default/files/_rotation-images/slide-2-new.jpg

    Delivering Innovative Therapies

    Through groundbreaking technology, rEVO Biologics is changing the way rare diseases are treated.

News Releases

rEVO Biologics, Inc. Announces Enrollment of First Patient in...

Wednesday, July 23, 2014

FRAMINGHAM, Mass., July 23, 2014 — rEVO Biologics, Inc., a subsidiary of LFB Biotechnologies, today announced the enrollment of the first patient in its Phase 3 clinical trial of ATryn® [antithrombin (Recombinant)], for the treatment of preeclampsia during the 24th to 28th week of pregnancy, or early onset preeclampsia. The objective of the PRESERVE-1 trial is to assess whether ATryn prolongs pregnancy in mothers with early onset preeclampsia and consequently reducing the high rates of neonatal mortality and disability caused by this condition.


The first patient was enrolled by Alan Tita, M.D., Ph.D., Professor of Obstetrics and Gynecology and his team at the University of Alabama, Birmingham. “As a physician faced with the difficult challenge of managing preeclampsia early in pregnancy, I see first-hand the significant need for new medicines to safely extend pregnancy and give a baby more time to develop in...

Contact Us +